

	Placebo	Natalizumab	OR (a)	Two-sided 90% Confidence Interval	One-sided p-value (b)
Number of subjects in the MITT population	82	77			
Day 30	81 (100)	72 (100)	1.30	[ 0.80, 2.10]	0.077
0	0	5 ( 7)			
1	7 ( 9)	8 ( 11)			
2	14 ( 17)	8 ( 11)			
3	17 ( 21)	17 ( 24)			
4	22 ( 27)	14 ( 19)			
5	13 ( 16)	11 ( 15)			
6	8 ( 10)	9 ( 13)			

Note: The MITT population is defined as all subjects who were randomized and have received the entire infusion of study treatment.

(a)Odds ratio from a proportional-odds logistic regression model assuming a common odds ratio across all cut points of the mRS score. Covariates include baseline DWI volume (< median vs >= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).

(b)P-value based on Van Elteren's test, adjusting for baseline DWI volume (< median vs >= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).